Vise Technologies Inc. increased its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK – Free Report) by 52.5% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 180,092 shares of the company’s stock after purchasing an additional 61,968 shares during the period. Vise Technologies Inc.’s holdings in Takeda Pharmaceutical were worth $3,276,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in the stock. Renaissance Technologies LLC grew its holdings in Takeda Pharmaceutical by 14.2% during the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock valued at $55,358,000 after buying an additional 370,800 shares in the last quarter. Quantinno Capital Management LP lifted its holdings in shares of Takeda Pharmaceutical by 20.6% in the first quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock worth $23,878,000 after buying an additional 219,999 shares in the last quarter. Assetmark Inc. lifted its holdings in shares of Takeda Pharmaceutical by 45.8% in the first quarter. Assetmark Inc. now owns 227,616 shares of the company’s stock worth $4,215,000 after buying an additional 71,496 shares in the last quarter. Bleakley Financial Group LLC lifted its holdings in shares of Takeda Pharmaceutical by 19.0% in the first quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company’s stock worth $7,993,000 after buying an additional 68,844 shares in the last quarter. Finally, Royal Bank of Canada boosted its position in shares of Takeda Pharmaceutical by 11.0% in the first quarter. Royal Bank of Canada now owns 614,851 shares of the company’s stock valued at $11,386,000 after acquiring an additional 60,725 shares during the period. Institutional investors own 9.17% of the company’s stock.
Insider Transactions at Takeda Pharmaceutical
In other news, General Counsel Anne Furney sold 30,868 shares of Takeda Pharmaceutical stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $527,842.80. Following the completion of the sale, the general counsel owned 204,298 shares in the company, valued at approximately $3,493,495.80. This trade represents a 13.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Deidre Greenway sold 12,980 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $18.11, for a total value of $235,067.80. Following the transaction, the insider directly owned 40,049 shares of the company’s stock, valued at $725,287.39. The trade was a 24.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 627,457 shares of company stock worth $10,981,175. 0.04% of the stock is owned by insiders.
Wall Street Analyst Weigh In
Several equities analysts recently commented on the stock. Zacks Research raised shares of Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 30th. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings raised shares of Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Takeda Pharmaceutical presently has an average rating of “Buy”.
Check Out Our Latest Research Report on Takeda Pharmaceutical
Takeda Pharmaceutical Price Performance
Takeda Pharmaceutical stock opened at $21.07 on Thursday. Takeda Pharmaceutical Co. has a 52 week low of $13.49 and a 52 week high of $21.22. The business has a 50-day simple moving average of $19.01 and a 200 day simple moving average of $17.62. The company has a quick ratio of 0.60, a current ratio of 1.15 and a debt-to-equity ratio of 0.56. The stock has a market cap of $67.50 billion, a price-to-earnings ratio of 11.86 and a beta of -0.02.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes medicines for patients worldwide, with a focus on areas of significant unmet medical need. Its principal therapeutic areas include gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.
Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, and medicines for certain blood cancers and rare conditions.
Featured Articles
- Five stocks we like better than Takeda Pharmaceutical
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co. (NYSE:TAK – Free Report).
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
